FOLD vs. EXAS, EXEL, RGEN, MDGL, HALO, IONS, ALKS, LGND, GERN, and MNKD
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Geron (GERN), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.
Amicus Therapeutics vs.
Exact Sciences (NASDAQ:EXAS) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
Exact Sciences has a net margin of -7.95% compared to Amicus Therapeutics' net margin of -21.21%. Exact Sciences' return on equity of -6.17% beat Amicus Therapeutics' return on equity.
In the previous week, Exact Sciences had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 12 mentions for Exact Sciences and 11 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.06 beat Exact Sciences' score of 0.78 indicating that Amicus Therapeutics is being referred to more favorably in the news media.
Exact Sciences received 450 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Amicus Therapeutics an outperform vote while only 73.01% of users gave Exact Sciences an outperform vote.
88.8% of Exact Sciences shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Exact Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Exact Sciences currently has a consensus target price of $72.94, suggesting a potential upside of 29.09%. Amicus Therapeutics has a consensus target price of $16.88, suggesting a potential upside of 87.08%. Given Amicus Therapeutics' higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Exact Sciences.
Amicus Therapeutics has lower revenue, but higher earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Exact Sciences beats Amicus Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FOLD) was last updated on 1/13/2025 by MarketBeat.com Staff
Free FOLD Stock Alerts